<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01050829</url>
  </required_header>
  <id_info>
    <org_study_id>13297</org_study_id>
    <nct_id>NCT01050829</nct_id>
  </id_info>
  <brief_title>Gadobutrol Magnevist-controlled Body Study</brief_title>
  <official_title>A Multi-center/Multi-national, Randomized, Controlled, Single-blind, Group Comparison Phase 3 Study to Determine the Efficacy and Safety of Gadobutrol 1.0 Molar in Comparison to Magnevist Following Single Injection in Patients Referred for Contrast-enhanced MRI of the Body/Extremities Regions (Breast, Heart, Abdomen, Kidney, Pelvis, or Extremities)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to look at the safety (what are the side effects) and efficacy&#xD;
      (how well does it work) of gadobutrol when used for taking MR images of the body/extremities&#xD;
      regions. The results of the MRI with gadobutrol injection will be compared to the results of&#xD;
      MR images taken without contrast and with the results of the MR images taken with Magnevist.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The total score of the following 3 visualization parameters is used for primary variable: Degree of contrast enhancement; Border delineation; Internal morphology.</measure>
    <time_frame>At Day 0</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensitivity and specificity for the detection of malignant lesions</measure>
    <time_frame>At Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exact match of the MR diagnosis with the final clinical diagnosis based on medical records up until 3 months after the scan</measure>
    <time_frame>At Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Confidence in diagnosis</measure>
    <time_frame>At Day 0</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">370</enrollment>
  <condition>Magnetic Resonance Imaging</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gadobutrol (Gadovist, BAY86-4875)</intervention_name>
    <description>Single administration at a dose of 0.1 mmol/kg</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gadopentetate Dimeglumine (Magnevist, BAY86-4882)</intervention_name>
    <description>Single administration at a dose of 0.1 mmol/kg</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Is at least 20 years of age&#xD;
&#xD;
          -  Is referred for a contrast-enhanced MRI of the body/extremities based on current&#xD;
             clinical symptoms or results of a previous imaging procedure&#xD;
&#xD;
          -  Is willing to undergo the routine contrast-enhanced MRI examinations&#xD;
&#xD;
          -  Is willing and able to complete all study procedures specified in the protocol&#xD;
&#xD;
          -  Subject is male, or is female not of childbearing potential, or is female of&#xD;
             childbearing potential who is using any medically accepted means of contraception and&#xD;
             has a negative urine pregnancy test prior to the administration of gadobutrol or&#xD;
             Magnevist&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Is a female subject who is pregnant or nursing&#xD;
&#xD;
          -  Has received any investigational product or has participated in any other clinical&#xD;
             trial within 2 weeks prior to enrolling in this study&#xD;
&#xD;
          -  Has been previously enrolled in this study or any other study using gadobutrol&#xD;
&#xD;
          -  Has any contraindication to the MRI examinations or the use of Gd-containing contrast&#xD;
             agents&#xD;
&#xD;
          -  Has a history of severe allergic or anaphylactoid reaction to any allergen including&#xD;
             drugs and contrast agents&#xD;
&#xD;
          -  Has received any contrast agent within 24 hours prior to the study MRI&#xD;
&#xD;
          -  Has a glomerular filtration rate value &lt;30 mL/min/1.73m2 derived from a serum&#xD;
             creatinine result within 4 weeks prior to study enrollment&#xD;
&#xD;
          -  Is considered clinically unstable or his/her clinical course during the study period&#xD;
             is unpredictable (eg, due to previous surgery, acute renal failure)&#xD;
&#xD;
          -  Has severe cardiovascular disease (eg, acute myocardial infarction (&lt;14 days),&#xD;
             unstable angina, congestive heart failure New York Heart Association class IV) or&#xD;
             acute stroke (&lt;48 hours)&#xD;
&#xD;
          -  Patients with acute renal insufficiency of any severity due to hepato-renal syndrome&#xD;
             or in the perioperative liver transplantation period&#xD;
&#xD;
          -  Has any contraindication to Magnevist according to the package insert&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shanghai</city>
        <zip>200233</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kamogawa</city>
        <state>Chiba</state>
        <zip>296-0041</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Matsuyama</city>
        <state>Ehime</state>
        <zip>791-0280</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chikushino</city>
        <state>Fukuoka</state>
        <zip>818-8516</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <zip>650-0047</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sunto</city>
        <state>Shizuoka</state>
        <zip>411-8777</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>113-8431</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukuoka</city>
        <zip>812-0033</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>150-713</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>158-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <study_first_submitted>January 13, 2010</study_first_submitted>
  <study_first_submitted_qc>January 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2010</study_first_posted>
  <last_update_submitted>December 26, 2014</last_update_submitted>
  <last_update_submitted_qc>December 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2014</last_update_posted>
  <responsible_party>
    <name_title>Therapeutic Area Head</name_title>
    <organization>Bayer Healthcare AG</organization>
  </responsible_party>
  <keyword>Magnetic resonance imaging</keyword>
  <keyword>Tumor</keyword>
  <keyword>Contrast media</keyword>
  <keyword>Gadobutrol</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

